Literature DB >> 21699582

Older patients suffer from adverse histopathological features after radical cystectomy.

Michael Rink1, Roland Dahlem, Luis Kluth, Sarah Minner, Sascha A Ahyai, Christian Eichelberg, Margit Fisch, Felix Kh Chun.   

Abstract

OBJECTIVES: Radical cystectomy (RC) remains a complex procedure in older patients. Perioperative morbidity can be significant and it can represent a limitation for its indication in this population. The aim of the present study was to evaluate the outcomes of RC in elderly patients from a large single-center cohort.
METHODS: A total of 447 patients who underwent RC between 1996 and 2009 at our institution were considered. Patients were stratified by age (≤70 vs >70 years). Logistic regression analyses were carried out comparing both groups regarding clinical, perioperative and histopathological findings, as well as complications according to the modified Clavien system and survival.
RESULTS: Data of 390 patients were available for the analysis. Of these, 265 (67.9%) versus 125 (32.1%) patients were <70 versus ≥70 years-of-age. The median age was 61 and 75 years, respectively. In the elderly, ASA score (P < 0.001), delay between transurethral resection of the bladder (TURBT) and RC (P = 0.004), and number of perioperative blood transfusions (P = 0.002) were significantly higher. Additionally, a clear trend towards higher stages (pT3-4) was observed (P = 0.04). However, complications, and overall and cancer-specific mortality were not increased in older patients. Finally, age was identified as a significant risk factor for upstaging (P = 0.04). Upstaging between TURBT and final histopathology in patients <70 versus ≥70 years occurred in 45% versus 58%, respectively (P = 0.03).
CONCLUSIONS: RC is equally feasible in older patients without increasing morbidity or mortality. On the contrary, older patients have a higher risk of significant upstaging and advanced stages at final histopathology. These findings suggest that RC should neither be delayed in nor withheld from elderly patients.
© 2011 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2011        PMID: 21699582     DOI: 10.1111/j.1442-2042.2011.02794.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

Review 1.  [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies].

Authors:  M Rink; F K Chun; T F Chromecki; H Fajkovic; R Dahlem; M Fisch; S F Shariat
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

Review 2.  Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer.

Authors:  Marianne Schmid; Shahrokh F Shariat; Armin Soave; Oliver Engel; Margit Fisch; Michael Rink
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

3.  Evaluation and Management of the Geriatric Urologic Oncology Patient.

Authors:  Maxim J McKibben; Angela B Smith
Journal:  Curr Geriatr Rep       Date:  2015-03

Review 4.  Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014.

Authors:  Mario W Kramer; Mathias Wolters; Hannes Cash; Stephan Jutzi; Florian Imkamp; Markus A Kuczyk; Axel S Merseburger; Thomas R W Herrmann
Journal:  World J Urol       Date:  2014-06-17       Impact factor: 4.226

Review 5.  Treatment of bladder cancer in the elderly.

Authors:  Annette Erlich; Alexandre R Zlotta
Journal:  Investig Clin Urol       Date:  2016-05-27

Review 6.  Thulium laser treatment for bladder cancer.

Authors:  Wei Wang; Haitao Liu; Shujie Xia
Journal:  Asian J Urol       Date:  2016-05-25

7.  Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?

Authors:  Junjie Tian; Junjie Sun; Guanghou Fu; Zhijie Xu; Xiaoyi Chen; Yue Shi; Baiye Jin
Journal:  Transl Androl Urol       Date:  2021-01

Review 8.  A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond.

Authors:  Jeffrey J Leow; Wei Shen Tan; Wei Phin Tan; Teck Wei Tan; Vinson Wai-Shun Chan; Kari A O Tikkinen; Ashish Kamat; Shomik Sengupta; Maxwell V Meng; Shahrokh Shariat; Morgan Roupret; Karel Decaestecker; Nikhil Vasdev; Yew Lam Chong; Dmitry Enikeev; Gianluca Giannarini; Vincenzo Ficarra; Jeremy Yuen-Chun Teoh
Journal:  Front Surg       Date:  2022-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.